Factor V Leiden and the Slovak Population;Faktor V Leiden a Slovenská Populace

Vnitrni Lekarstvi

Volumn 49, Issue 11, 2003, Pages 845-850

  Hudeček, Jan ^a,b   Dobrotova M ^a   Hybenova J ^a   Ivankova J ^a   Melus V ^a   Pullmann, R ^a   Kubisz, P ^a  

^a Martinska Fakultna Nemocnica   (Slovakia)

^b NONE   (Slovakia)

Author keywords

Factor V Leiden; Myocardial infarction; Resistance to activated protein C; Slovak population; Thrombosis

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN; NICOTINE;

ARTICLE; CAUCASIAN; CONSANGUINITY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPOPROTEINEMIA; FREQUENCY ANALYSIS; GENE MUTATION; GENETIC ASSOCIATION; GEOGRAPHIC DISTRIBUTION; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MOLECULAR BIOLOGY; OBESITY; POPULATION RISK; PREVALENCE; PROTEIN ANALYSIS; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE; SUBSTANCE ABUSE; THROMBOGENESIS; THROMBOPHILIA; THROMBOSIS; VENOUS CIRCULATION;

ACTIVATED PROTEIN C RESISTANCE; ADOLESCENT; ADULT; AGED; FACTOR V; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; POINT MUTATION; RETROSPECTIVE STUDIES; SLOVAKIA; THROMBOSIS;

EID: 0345308333     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Bajzar, L., Nesheim, M. E., Tracy, P. B.: The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood, 1996; 88 (6): 2093-2100
2. Bertina, R. M., Koeleman, B. P. C., Koster, T. et al.: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature, 1994; 369: 64-67
3. Björgell, O., Nilsson, P. E., Nilsson, J. A. et al.: Location and extent of deep vein thrombosis in patients with and without FV:R506Q mutation. Thromb. Haemost., 2000; 83 (5): 648-651
4. Camire, R. M., Pollak, E. S., Kaushansky, K. et al.: Secretable human platelet-derived factor V originates from the plasma pool. Blood, 1998; 92 (9): 3035-3041
5. Dahlbäck, B.: Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutatin. Semin. Thromb. Hemost., 1999; 25 (3): 273-289
6. De Stefano, V., Chiusolo, P., Paciaroni, K. at al.: Epidemiology of factor V Leiden: clinical implications. Semin. Thromb. Hemost., 1998; 24 (4): 367-379
7. Dulíček, P., Šafá̌ová, M., Chrobák, L.: Mutace FV Leiden - nejčastější rizikový factor pro vznik žilní trombózy. Hematológia a transfuziológia, 1997; 7 (4): 6-9
8. Hoekema, L., Castoldi, E., Tans, G. et al.: Functional properties of factor V and factor Va encoded by the R2-gene. Thromb. Haemost., 2001; 85 (1): 75-81
9. Hudeček, J., Ivanková, J., Dobrotová, M. et al.: Analýza fenotypu rezistence na aktivovaný protein C (APC-rezistence). Vnitř. Lék., 1999; 45 (12): 723-728
10. Inbal, A., Freimark, D., Modan, B. et al.: Synergistic effects of prothromobotic polymorphisms and atherogenic factors on the risk of myocardial infarction in young males. Blood, 1999; 93 (7): 2186-2190
11. Janků, L., Bartoníčková, A.: Rizikový faktor trombózy - bodová mutace G1691A v genu faktoru V ajejí prevalence v České republice. Hematológia a transfuziológia, 2000; 10 (2): 91-95
12. Lane, D. A., Grant, P. J.: Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood, 2000; 95 (5): 1517-1532
13. Madisen, L., Hoar, D. I., Holroyd, C. D. et al.: DNA banking: the effects of storage of blood and isolated DNA on the integrity of DNA. Am. J. Med. Genet., 1987; 27 (2): 379-390
14. Makris, M., Rosendaal, F. R., Preston, F. E.: Familial thrombophilia: genetic risk factors and management. J. Int. Med., 1997; 242 (Suppl. 740): 9-15
15. Mansourati, J., Da Costa, A., Munier, S. et al.: Prevalence of factor V Leiden in patients with myocardial infarction and normal coronary angiography. Thromb. Haemost., 2000; 83 (6): 822-825
16. Martinelli, I., Mannucci, P. M., De Stefano, V. et al.: Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood, 1998; 92 (7): 2353-2358
17. R506Q by activated protein C. J. Biol. Chem., 1995; 270: 21158-21166
18. Rosendaal, F. R.: Risk factors for venous thrombotic disease. Thromb. Haemost., 1999; 82 (2): 610-619
19. Rosendaal, F. R., Siscovick, D. S., Schwartz, S. M. et al.: Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood, 1997; 89 (8): 2817-2821
20. Shen, L., Dahlbäck, B.: Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. J. Biol. Chem., 1994; 269: 18735-18738
21. Simmonds, R. E., Hermida, J., Rezende, S. M. et al.: Haemostatic genetic risk factors in arterial thrombosis. Thromb. Haemost., 2001; 86 (3): 374-385
22. Siscovick, D. S., Schwartz, S. M., Rosendaal, F. R. et al.: Thrombosis in the young: effect of atherosclerotic risk factors on the risk of myocardial infarction associated with prothrombotic factors. Thromb. Haemost., 1997; 78 (1): 7-12
23. Taube, J., McWilliam, N., Luddington, R. et al.: Activated protein C resistance: effect of platelet activation, platelet-derived microparticles, and atherogenic lipoproteins. Blood, 1999; 93 (11): 3792-3797
24. Tosetto, A., Castaman, G., Cappellari, A. et al.: The VITA project: heritability of resistance to activated protein C. Thromb. Haemost., 2000; 84 (5): 811-814.
25. Trnovec, T., Dzúrik, R.: Standardné diagnostické postupy. 1. vyd. Osveta: Martin, 1998. 832 s.
26. Turkstra, F., Karemaker, R., Kuijer, P. M. M. et al.: Is the prevalence of the factor V Leiden mutation in patients with pulmonary embolism and deep vein thrombosis really different? Thromb. Haemost., 1999; 81 (2): 345-348
27. Zivelin, A., Griffin, J. H., Xu, X. et al.: A single genetic origin for a common Caucasian risk factor for venous thrombosis. Blood, 1997; 89 (2): 397-402
28. Zöller, B., Svensson, P. J., He, X. et al.: Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J. Clin. Invest., 1994; 94: 2521-2524